| Website | adnexustx.com |
| Category | BioTech |
| Phone | 781-891-3745 |
| Employees |
| TOTAL | $42.5M |
| VENTURE FUNDING TOTAL | $42.5M |
| Series B, 6/06 Venrock Atlas Venture Flagship Ventures Polaris Venture Partners | $27M |
| Series C, 8/07 HBM BioVentures Atlas Venture Flagship Ventures Polaris Venture Partners Venrock | $15.5M |
Adnexus, a Bristol-Myers Squibb R&D Company, is leading the discovery and development of Adnectinsâ„¢, a novel, proprietary class of targeted biologics. Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to fight diseases across a broad range of therapeutic areas. Their proprietary technology for engineering these versatile proteins creates an opportunity to rapidly generate highly differentiated medicines.
